Open AccessComparative pharmacokinetics of a tumour‐targeting therapy candidate rh‐IFNα2a –NGR with rh‐IFNα2a administered intravenously in mice and rats
Author(s) -
Wang XueXi,
Lu Li,
Song ChunLi,
Qian WeiNa,
Zhang ShengYan,
Zhang YingQi,
Wu YongJie
Publication year - 2013
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/jphp.12022
Subject(s) - pharmacokinetics , pharmacology , medicine , antibody , immunohistochemistry , chemistry , immunology
Objectives rh‐IFNα2a‐NGR is a promising anti‐tumor candidate. The aim of present study was to compare pharmacokinetics of rh‐IFNα2a‐NGR with rh‐IFNα2a . Methods Pharmacokinetics and elimination were investigated after intravenous administration to mice and rats. Compared tumor and tissue distribution profiles between rh‐IFNα2a‐NGR and rh‐IFNα2a were illustrated in the tumor transplanted mice of SP 2/0 myeloma. Double antibody sandwich ELISA method was used to assess the level of both rh‐IFNα2a‐NGR and rh‐IFNα2a in serum, tissue, bile and urine. Key findings After a single intravenous administration, the pharmacokinetic characters of rh‐IFNα2a‐NGR and rh‐IFNα2a were described using a two‐compartment model. No significant differences were observed between the two drugs in pharmacokinetic and elimination data. However, the concentration of rh‐IFNα2a‐NGR in tumor was 5.34 times and 1.52 times as high as that of rh‐IFNα2a at 0.5 h ( P < 0.01) and 1 h. In addition, immunohistochemical stain displayed rh‐IFNα2a‐NGR was predominantly located in tumor vascular tissues. Conclusions rh‐IFNα2a‐NGR could be an agent for tumor vascular‐targeting therapy and these findings provided references for further clinical study.